TREA

90788388 - BIOHAVEN PHARMACEUTICALS

Follow

Information

  • Trademark
  • 90788388
  • Serial Number
    90788388
  • Registration Number
    6629316
  • Filing Date
    June 22, 2021
    3 years ago
  • Registration Date
    January 25, 2022
    3 years ago
  • Transaction Date
    May 13, 2023
    a year ago
  • Status Date
    January 25, 2022
    3 years ago
  • Published for Opposition Date
    November 09, 2021
    3 years ago
  • Location Date
    January 25, 2022
    3 years ago
  • First Use Anywhere Date
    March 01, 2020
    5 years ago
  • First Use In Commerce Date
    March 01, 2020
    5 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    CLIFFORD, MEGAN NICOLE
  • Attorney Docket Number
    4501.0910000
    Attorney Name
    Monica Riva Talley
    Law Office Assigned Location Code
    M20
  • Owners
Information
Mark Drawing Code
3000
Mark Identification
BIOHAVEN PHARMACEUTICALS
Case File Statements
  • DM0000: The mark consists of the stylized wording "BIOHAVEN PHARMACEUTICALS", with two outlined hexagon shapes positioned above the letter "I" and one outlined hexagon shape positioned below the letter "I", and the wording "PHARMACEUTICALS" appearing in smaller print below the wording "BIOHAVEN".
  • GS0051: Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in Amyotrophic Lateral Sclerosis (ALS), pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in Alzheimer's disease (AD), disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use
  • D10000: "PHARMACEUTICALS"
  • GS0421: Pharmaceutical research and development in the fields of headache, facial pain, impulse control disorders, neurological disorders, and neurodegenerative disorders, and consultation provided in conjunction therewith
Case File Event Statements
  • 4/17/2023 - a year ago
    22 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 4/17/2023 - a year ago
    21 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 4/17/2023 - a year ago
    20 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 4/17/2023 - a year ago
    19 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 4/17/2023 - a year ago
    18 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 6/23/2022 - 2 years ago
    17 - ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Type: ASCK
  • 1/25/2022 - 3 years ago
    16 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 1/12/2022 - 3 years ago
    15 - ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Type: ASCK
  • 11/9/2021 - 3 years ago
    14 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 11/9/2021 - 3 years ago
    13 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/20/2021 - 3 years ago
    12 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/6/2021 - 3 years ago
    11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/21/2021 - 3 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 9/21/2021 - 3 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/21/2021 - 3 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/10/2021 - 3 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 9/10/2021 - 3 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 9/10/2021 - 3 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/8/2021 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/8/2021 - 3 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 9/7/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/25/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP